Publications dans lesquelles il/elle collabore avec ANDRES MARTIN ASPAS (11)

2023

  1. Expression profile of microRNAs related with viral infectivity, inflammatory response, and immune activation in people living with HIV

    Frontiers in Microbiology, Vol. 14

2021

  1. Neutrophil Expression of T and B Immunomodulatory Molecules in HIV Infection

    Frontiers in Immunology, Vol. 12

2019

  1. Antiretroviral therapy partially improves the abnormalities of dendritic cells and lymphoid and myeloid regulatory populations in recently infected HIV patients

    Scientific Reports, Vol. 9, Núm. 1

2017

  1. Soluble membrane receptors, interleukin 6, procalcitonin and C reactive protein as prognostic markers in patients with severe sepsis and septic shock

    PLoS ONE, Vol. 12, Núm. 4

2015

  1. Fiebre Q aguda: riesgo de desarrollo de endocarditis

    Revista Clinica Espanola, Vol. 215, Núm. 5, pp. 265-271

  2. Immune activation response in chronic HIV-infected patients: Influence of hepatitis C virus coinfection

    PLoS ONE, Vol. 10, Núm. 3

2014

  1. Predictors of early mortality in very elderly patients with bacteremia: A prospective multicenter cohort

    International Journal of Infectious Diseases, Vol. 26, pp. 83-87

2012

  1. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: A propensity score-based analysis

    Antimicrobial Agents and Chemotherapy, Vol. 56, Núm. 1, pp. 472-478

  2. La valoración de RNA del virus de la hepatitis C realizada a las 12 semanas de finalizar el tratamiento predice la respuesta virológica sostenida en enfermos con coinfección por VIH y VHC

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 30, Núm. 1, pp. 15-17

2006

  1. Structured intermittent interruption of chronic HIV infection treatment with highly active antiretroviral therapy: Effects on leptin and TNF-α

    AIDS Research and Human Retroviruses, Vol. 22, Núm. 4, pp. 307-314

2005

  1. Absence of favourable changes in circulating levels of interleukin-16 or β-chemokine concentration following structured intermittent interruption treatment of chronic human immunodeficiency virus infection

    Clinical Microbiology and Infection, Vol. 11, Núm. 1, pp. 57-62